HOME >> BIOLOGY >> NEWS
LIAI finding gives boost to bioinformatics use in fighting disease

SAN DIEGO (June 16, 2006) The use of computers to advance human disease research known as bioinformatics -- has received a major boost from researchers at the La Jolla Institute for Allergy & Immunology (LIAI), who have used it to successfully predict immune response to one of the most complex viruses known to man the vaccinia virus, which is used in the smallpox vaccine. Immune responses, which are essentially how the body fights a disease-causing agent, are a crucial element of vaccine development.

"We are excited because this further validates the important role that bioinformatics can play in the development of diagnostic tools and ultimately vaccines," said Alessandro Sette, Ph.D., an internationally known vaccine expert and head of LIAI's Emerging Infectious Disease and Biodefense Center. "We've shown that it can successfully reveal with a very high degree of accuracy -- the vast majority of the epitopes (targets) that would trigger an effective immune response against a complex pathogen."

Bioinformatics holds significant interest in the scientific community because of its potential to move scientific research forward more quickly and at less expense than traditional laboratory testing.

The findings were published this week in a paper, "A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus," in the online version of the journal Nature Biotechnology. LIAI scientist Magdalini Moutaftsi was the lead author on the paper.

While bioinformatics which uses computer databases, algorithms and statistical techniques to analyze biological information -- is already in use as a predictor of immune response, the LIAI research team's findings were significant because they demonstrated an extremely high rate of prediction accuracy (95 percent) in a very complex pathogen the vaccinia virus. The vaccinia virus is a non-dangerous virus used in the smallpox vaccine because i
'"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
16-Jun-2006


Page: 1 2 3

Related biology news :

1. New findings challenge established views on human genome
2. New findings challenge established views about human genome
3. Depiction of findings selected as 2007 Image of the Year by Society for Nuclear Medicine
4. LIAI scientists make important finding on cytomegalovirus transmission
5. New findings in smell and taste
6. Study produces conflicting findings on the use of anti-anemia drug in cancer patients
7. Bloods clotting cells harbor ticking time bombs, finding may help extend blood supply
8. Stress and nerve cells survival in rats; finding may open window for depression treatment
9. CMU researcher publishes anole lizard findings
10. Surprising airbag hazards among research findings at hearing safety conference
11. Satellite data vital to UN climate findings

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: LIAI finding gives boost bioinformatics use fighting disease

(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - handyem ... centralized around the incorporation of handyem,s HPC-150 portable ... laboratory, the Mo-POD™. This unprecedented model of mobile ... Conference at the Pennsylvania ... June 15 th to 18 th ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... fingerprint sensors in the company,s portfolio from one of its ... planned to mainly take place during the third quarter 2015. ... Asia . Jörgen Lantto, CEO of ...   the   growing interest from smartphone OEMs in integrating ...
(Date:6/15/2015)... June 16, 2015 According to ... by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, ... 2020" published by MarketsandMarkets, The Natural Language Processing Market ... CAGR of 18.4% for the forecast period 2015-2020. ... 46 F igures spread   through 155 P ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech ... surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, Inc ... provider of surgical instruments to the Spine Industry. The acquisition of Turner Medical ...
(Date:7/1/2015)... , July 1, 2015   Decision ... frequently cited advantages of Otezla are its oral ... profile, as reported by surveyed rheumatologists. Otezla was ... for the treatment of active psoriatic arthritis in ... current standard of care includes conventional oral treatments ...
(Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan ... lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s Startup ... prizes of US$15,000 and a period of expert mentorship from a senior industry figure ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
Cached News: